Hikma Pharmaceuticals PLC (HIK) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Okay. Good morning, everyone. I'm Guy Featherston, Investor Relations. Before we start, I'd like to remind you that any forward-looking statements or projections made by HICMA during this call are made in good faith based on information currently available and are subject to risks and uncertainties that may cause actual results to differ materially from those projected. For further information, please see the Principal Risks and Uncertainties section in HICMA's annual report. Thank you for joining this Q&A meeting for Hikmah's 2025 full year results. Our pre-recorded presentation is available on our website and this will be a Q&A session. We're joined today by Saeed Darwaza, CEO, Mazen Darwaza, Executive Vice Chairman and Deputy CEO, Khaled Nobilsi, Deputy CEO, North America and Europe, Afrin Frederick-Stottir, President, US and Global Head of R&D, We're also joined by John Kafer, who heads up the US Injectables commercial business, and we have Arab Kirby, recently appointed Acting CFO, and Susan Ringdahl, Investor Relations, also in the room. And with that, I will hand over to Saeed. Thank you very much, and good morning everybody, and to my old friends, hello again. The decision for me to take over as CEO again was not really a very easy decision. giving up the beach and the sun and the good life was difficult. But I really felt very strongly compelled to do this. I remember before we IPO-ed, we were discussing the ideas of IPO-ing and not IPO-ing, and my father saying, my worry is that one day the team will lose sight of the long term and start looking at short term and short term wins. This is the only thing that I'm worried about. And frankly, in many ways, this is what happened, I think. The company had sort of started looking at short-term wins and fixation on...